D B-cells were also reduced but numbers did not reach significance.Significant inhibition of graft and spleen IL17and Th1 genes in vivo with Fenofibrate. Corroborating the findings ofFenofibrate on anti-CD3/CD28 stimulated human PBMCs, Fenofibrate treatment in vivo in cardiac transplanted mice resulted in reduced gene expression levels of IFN- c and IL17A (Figure 6A, 6B). IL17A expression in the Fenofibrate treated micewas only detectable in the transplanted hearts and did not reach 1655472 the threshold of detection by QPCR in the recipients’ spleens at POD7. In grafts IL17 was significantly lower compared to no treatment (6a, p = 0.0462). In spleens, Fenofibrate significantly reduced IFN-c expression (6b, p = 0.0094) whereas reduction of graft IFN-y expression did not quite reach the significance threshold of p = 0.05 when compared to no-treatment by two sided Student T-test (6a). Next, we further elucidated the efficacy of Fenofibrate and expanded graft (Figure 6A) and spleen (Figure 6B) gene expression analyses to genes up- and downstream of the Th1 response and IL17 pathway: Fenofibrate reduced the IL17 stimulating cytokines IL-1b, and TGF-b, as well as of IL-17 downstream TNF in both mice allografts and spleens. IL-6 which also is upstream of IL17 and together with IL1-b and TGFb important for activating the IL17 response was significantlyDrug Repositioning Fenofibrate for TransplantationFigure 3. Fenofibrate gene expression in human PBMC: Fenofibrate regulates IL17 and IFN-c gene expression in CD3/CD28 stimulated human PBMC. PBMC from healthy individuals (n = 5) were stimulated with CD3/CD28 antibodies (S) leading to significant upregulation of IL17 and IFN-c which was inhibited by Fenofibrate (S+FF). Values represent mean fold changes versus non-stimulated (NS) cells plus Standard error of mean calculated using DDCt method and 18S as Hesperidin web endogenous control gene; experiments were performed in triplicates. Student T-test for paired data: * p-value ,0.05. Individual p-values are displayed in Table 3. doi:10.1371/journal.pone.0056657.3-Bromopyruvic acid site greduced by Fenofibrate in mice allografts only. The Th1 response was further investigated quantifying the stimulating IL-12 cytokine expression as well as the Th1 transcription factor STAT4. Fenofibrate significantly decreased expression of both genes in mouse spleens, STAT4 was additionally significantly decreased in the in the graft as compared to mice that were not-treated with Fenofibrate for AR. QPCR in grafts and spleens from Cys treated mice at POD7 validated the preferential inhibition of Th1 responses by Cys seen in reduced graft IFN-y (p = 0.0101) and STAT4 (p = 0.0091) expression, whereas IL17A was not affected by Cys (p = 0.2180) but even showed a trend towards higher expression. To address the question, whether the effect of Fenofibrate to inhibit the IL17 pathway is more dependent on the related orphan receptors RORc/RORa or on STAT3 (which induce Th17 cell differentiation), we performed additional QPCR for RORc, RORa and STAT3 expression in grafts and spleens from untreated and Fenofibrate treated mice at POD7. There was no significant difference with treatment in expression of either RORc (p = 0.26 in the graft; p = 0.59 in the spleen) or RORa Table 3. Effects of Fenofibrate on IFNG and IL17A expression in human PBMC: Fold changes (Fc) comparing stimulated (S) to no-stimulated (NS) PBMC (upper part) and comparing stimulated (S) to stimulated and Fenofibrate treated (S+FF) PBMC (lower part); directi.D B-cells were also reduced but numbers did not reach significance.Significant inhibition of graft and spleen IL17and Th1 genes in vivo with Fenofibrate. Corroborating the findings ofFenofibrate on anti-CD3/CD28 stimulated human PBMCs, Fenofibrate treatment in vivo in cardiac transplanted mice resulted in reduced gene expression levels of IFN- c and IL17A (Figure 6A, 6B). IL17A expression in the Fenofibrate treated micewas only detectable in the transplanted hearts and did not reach 1655472 the threshold of detection by QPCR in the recipients’ spleens at POD7. In grafts IL17 was significantly lower compared to no treatment (6a, p = 0.0462). In spleens, Fenofibrate significantly reduced IFN-c expression (6b, p = 0.0094) whereas reduction of graft IFN-y expression did not quite reach the significance threshold of p = 0.05 when compared to no-treatment by two sided Student T-test (6a). Next, we further elucidated the efficacy of Fenofibrate and expanded graft (Figure 6A) and spleen (Figure 6B) gene expression analyses to genes up- and downstream of the Th1 response and IL17 pathway: Fenofibrate reduced the IL17 stimulating cytokines IL-1b, and TGF-b, as well as of IL-17 downstream TNF in both mice allografts and spleens. IL-6 which also is upstream of IL17 and together with IL1-b and TGFb important for activating the IL17 response was significantlyDrug Repositioning Fenofibrate for TransplantationFigure 3. Fenofibrate gene expression in human PBMC: Fenofibrate regulates IL17 and IFN-c gene expression in CD3/CD28 stimulated human PBMC. PBMC from healthy individuals (n = 5) were stimulated with CD3/CD28 antibodies (S) leading to significant upregulation of IL17 and IFN-c which was inhibited by Fenofibrate (S+FF). Values represent mean fold changes versus non-stimulated (NS) cells plus Standard error of mean calculated using DDCt method and 18S as endogenous control gene; experiments were performed in triplicates. Student T-test for paired data: * p-value ,0.05. Individual p-values are displayed in Table 3. doi:10.1371/journal.pone.0056657.greduced by Fenofibrate in mice allografts only. The Th1 response was further investigated quantifying the stimulating IL-12 cytokine expression as well as the Th1 transcription factor STAT4. Fenofibrate significantly decreased expression of both genes in mouse spleens, STAT4 was additionally significantly decreased in the in the graft as compared to mice that were not-treated with Fenofibrate for AR. QPCR in grafts and spleens from Cys treated mice at POD7 validated the preferential inhibition of Th1 responses by Cys seen in reduced graft IFN-y (p = 0.0101) and STAT4 (p = 0.0091) expression, whereas IL17A was not affected by Cys (p = 0.2180) but even showed a trend towards higher expression. To address the question, whether the effect of Fenofibrate to inhibit the IL17 pathway is more dependent on the related orphan receptors RORc/RORa or on STAT3 (which induce Th17 cell differentiation), we performed additional QPCR for RORc, RORa and STAT3 expression in grafts and spleens from untreated and Fenofibrate treated mice at POD7. There was no significant difference with treatment in expression of either RORc (p = 0.26 in the graft; p = 0.59 in the spleen) or RORa Table 3. Effects of Fenofibrate on IFNG and IL17A expression in human PBMC: Fold changes (Fc) comparing stimulated (S) to no-stimulated (NS) PBMC (upper part) and comparing stimulated (S) to stimulated and Fenofibrate treated (S+FF) PBMC (lower part); directi.
